Biogen Idec 2nd-qtr sales and earnings top analysts expectations The Pharma Letter ... global pediatric studies for its long-lasting factor VIII and factor IX programs for hemophilia and completing enrollment in the Phase III A-LONG and B-LONG trials for the long-lasting blood factors as well as the Phase III DECIDE study of ... |
